This is understandable, as this protein appears to be the most critical angiogenic factor, and the blockade of VEGF-mediated pathways (by e.g., sorafenib) suppresses carcinogenesis and angiogenesis in HCC [5,7,8]. This evidence concerns the gene VEGFA and hepatocellular carcinoma.